Our product pipeline reflects a commitment to developing cutting-edge exosome-based therapies and nanodrugs to address critical medical needs and to improve patient outcomes across various indications.
PROGRAM
ExoPTEN
PNN targeting sequences
Exosomes and Stem Cells
INDICATION
Acute Spinal Cord Injury
Glaucoma
Several - CNS Traumatic Injury
Chronic Spinal Cord Injury
DISCOVERY
PRECLINICAL DEVELOPMENT
REGULATORYSTRATEGY
STUDIES FOR IND (Toxicity, Efficacy)
CLINICAL
COMMERCIAL
Collaboration with Inteligex leverages their novel targeted human stem cell platform which replaces key cell types lost due to traumatic injury or neurodegeneration